0001209191-22-056446.txt : 20221110
0001209191-22-056446.hdr.sgml : 20221110
20221110180047
ACCESSION NUMBER: 0001209191-22-056446
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221108
FILED AS OF DATE: 20221110
DATE AS OF CHANGE: 20221110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Karas Eric
CENTRAL INDEX KEY: 0001951287
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39756
FILM NUMBER: 221378904
MAIL ADDRESS:
STREET 1: C/O ARS PHARMACEUTICALS, INC.
STREET 2: 11682 EL CAMINO REAL, SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARS Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001671858
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811489190
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11682 EL CAMINO REAL, SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-771-9307
MAIL ADDRESS:
STREET 1: 11682 EL CAMINO REAL, SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Silverback Therapeutics, Inc.
DATE OF NAME CHANGE: 20160412
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-08
0
0001671858
ARS Pharmaceuticals, Inc.
SPRY
0001951287
Karas Eric
C/O ARS PHARMACEUTICALS, INC.
11682 EL CAMINO REAL, SUITE 120
SAN DIEGO
CA
92130
0
1
0
0
Chief Commercial Officer
Stock option (right to buy)
1.50
2022-11-08
4
A
0
614588
A
2032-05-24
Common Stock
614588
614588
D
25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
Received in exchange for a stock option to acquire 520,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $1.77 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.
/s/ Kathleen Scott, Attorney-in-Fact
2022-11-10